Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Online telehealth company Hims and Hers Health is launching weight-loss membership and treatment plans in the UK. The new service will offer drugs such as Novo Nordisk's Wegovy and Eli Lilly's ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...